S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

OncoSec Medical Stock Forecast, Price & News

-0.06 (-4.38%)
(As of 11/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
204,400 shs
Average Volume
646,339 shs
Market Capitalization
$51.36 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ONCS News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoSec Medical and its competitors with MarketBeat's FREE daily newsletter.

OncoSec Medical logo

About OncoSec Medical

OncoSec Medical, Inc. is a biotechnology company focused on designing, developing and commercializing therapies and proprietary medical approaches to stimulate and to guide an anti-tumor immune response for the treatment of cancer. Its lead product candidate, ImmunoPulse IL-12, uses an electroporation device, with the aim of reversing the immunosuppressive microenvironment in the treated tumor. The company was founded by Avtar S. Dhillon and Punit S. Dhillon on February 8, 2008 and is headquartered in Pennington, NJ.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$0.97 per share


Net Income
$-45.17 million
Pretax Margin




Free Float
Market Cap
$51.36 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.79 out of 5 stars

Medical Sector

833rd out of 1,391 stocks

Pharmaceutical Preparations Industry

399th out of 669 stocks

Analyst Opinion: 3.5Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

OncoSec Medical (NASDAQ:ONCS) Frequently Asked Questions

Is OncoSec Medical a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoSec Medical in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OncoSec Medical stock.
View analyst ratings for OncoSec Medical
or view top-rated stocks.

How has OncoSec Medical's stock been impacted by COVID-19 (Coronavirus)?

OncoSec Medical's stock was trading at $1.37 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ONCS stock has decreased by 4.4% and is now trading at $1.31.
View which stocks have been most impacted by COVID-19

When is OncoSec Medical's next earnings date?

OncoSec Medical is scheduled to release its next quarterly earnings announcement on Friday, December 10th 2021.
View our earnings forecast for OncoSec Medical

How were OncoSec Medical's earnings last quarter?

OncoSec Medical Incorporated (NASDAQ:ONCS) announced its quarterly earnings data on Sunday, March, 14th. The biotechnology company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.36) by $0.01.
View OncoSec Medical's earnings history

When did OncoSec Medical's stock split? How did OncoSec Medical's stock split work?

OncoSec Medical shares reverse split on Tuesday, May 21st 2019. The 1-10 reverse split was announced on Monday, May 20th 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 20th 2019. An investor that had 100 shares of OncoSec Medical stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for ONCS?

3 analysts have issued 12 month target prices for OncoSec Medical's stock. Their forecasts range from $10.00 to $12.00. On average, they anticipate OncoSec Medical's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 739.7% from the stock's current price.
View analysts' price targets for OncoSec Medical
or view top-rated stocks among Wall Street analysts.

Who are OncoSec Medical's key executives?

OncoSec Medical's management team includes the following people:
  • Robert J. DelAversano, Vice President-Finance & Controller (LinkedIn Profile)
  • Sandra Aung, Chief Clinical Development Officer & Senior VP
  • Keir Loiacono, Chief Compliance Officer & Vice President-Legal
  • Joe Smith, Vice President-Business Development
  • Bridget O'Keeffe, Vice President-Clinical Development

What is Punit Dhillon's approval rating as OncoSec Medical's CEO?

2 employees have rated OncoSec Medical CEO Punit Dhillon on Glassdoor.com. Punit Dhillon has an approval rating of 50% among OncoSec Medical's employees. This puts Punit Dhillon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of OncoSec Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OncoSec Medical investors own include Cytokinetics (CYTK), Inovio Pharmaceuticals (INO), XOMA (XOMA), Anavex Life Sciences (AVXL), Walt Disney (DIS), Idera Pharmaceuticals (IDRA), Sorrento Therapeutics (SRNE), Amarin (AMRN), Dynavax Technologies (DVAX) and Trevena (TRVN).

What is OncoSec Medical's stock symbol?

OncoSec Medical trades on the NASDAQ under the ticker symbol "ONCS."

Who are OncoSec Medical's major shareholders?

OncoSec Medical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Two Sigma Advisers LP (0.92%), Geode Capital Management LLC (0.62%), Renaissance Technologies LLC (0.27%), Bank of New York Mellon Corp (0.13%), Tocqueville Asset Management L.P. (0.13%) and Schonfeld Strategic Advisors LLC (0.06%). Company insiders that own OncoSec Medical stock include Alpha Holdings, Inc, Brian A Leuthner, Daniel J O'connor, Grand Pharmaceutical & H China, Robert J Delaversano, Robert J Delaversano, Sara Bonstein and Yuhang Zhao.
View institutional ownership trends for OncoSec Medical

Which major investors are selling OncoSec Medical stock?

ONCS stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and Schonfeld Strategic Advisors LLC. Company insiders that have sold OncoSec Medical company stock in the last year include Brian A Leuthner, Daniel J O'connor, and Robert J Delaversano.
View insider buying and selling activity for OncoSec Medical
or view top insider-selling stocks.

Which major investors are buying OncoSec Medical stock?

ONCS stock was purchased by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Geode Capital Management LLC, Bank of New York Mellon Corp, Goldman Sachs Group Inc., Tocqueville Asset Management L.P., HighTower Advisors LLC, and Citadel Advisors LLC. Company insiders that have bought OncoSec Medical stock in the last two years include Grand Pharmaceutical & H China, and Yuhang Zhao.
View insider buying and selling activity for OncoSec Medical
or or view top insider-buying stocks.

How do I buy shares of OncoSec Medical?

Shares of ONCS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OncoSec Medical's stock price today?

One share of ONCS stock can currently be purchased for approximately $1.31.

How much money does OncoSec Medical make?

OncoSec Medical has a market capitalization of $51.36 million. The biotechnology company earns $-45.17 million in net income (profit) each year or ($1.36) on an earnings per share basis.

How many employees does OncoSec Medical have?

OncoSec Medical employs 44 workers across the globe.

What is OncoSec Medical's official website?

The official website for OncoSec Medical is www.oncosec.com.

Where are OncoSec Medical's headquarters?

OncoSec Medical is headquartered at 3565 GENERAL ATOMICS COURT, SAN DIEGO CA, 92121.

How can I contact OncoSec Medical?

OncoSec Medical's mailing address is 3565 GENERAL ATOMICS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at (858) 662-6732, via email at [email protected], or via fax at 858-430-3832.

This page was last updated on 11/29/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.